Drug company Trinity Biotech reported a 22.6 per cent rise in quarterly revenues to $20.1 with US sales proving particularly strong.
The Co Wicklow based company said gross profit in the second quarter amounted to $10.3 million, representing a gross margin of 51.4 per cent. This compares to a gross profit of $8 million in the first quarter and a gross margin of 48.9 per cent.
Commenting on the results, Mr Rory Nealon, chief financial officer, said 12 per cent of the quarterly revenue growth was due to recent acquisitions and the remainder attributable to organic growth.
"We are particularly pleased with the performance of our US and international sales forces which have delivered this 11 per cent organic growth" he said.
Trinity Biotech's chief executive, Mr Ronan O'Caoimh the company's acquisitions of US drug distributor Adaltis and drug company Fitzgerald have integrated smoothly and will enhance the profitability of the group in the coming quarters.